| Entry |
|
|---|
| Name |
Viloxazine hydrochloride (USAN);
Qelbree (TN);
Vivalan (TN) |
|---|
| Product |
|
|---|
| Formula |
C13H19NO3. HCl
|
|---|
| Exact mass |
273.1132
|
|---|
| Mol weight |
273.75
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02924 UGT substrate
DG03188 UGT1A9 substrate
DG03187 UGT2B15 substrate
|
|---|
| Remark |
| Product (DG00956): | D02572<US> |
|
|---|
| Efficacy |
Antidepressant, Selective noradrenaline reuptake inhibitor (NRI) |
|---|
| Disease |
Attention deficit hyperactivity disorder [DS: H01895] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565], UGT1A9 [HSA: 54600], UGT2B15 [HSA: 7366]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06A ANTIDEPRESSANTS
N06AX Other antidepressants
N06AX09 Viloxazine
D02572 Viloxazine hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines
Viloxazine
D02572 Viloxazine hydrochloride (USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
DG00956 Viloxazine
D02572 Viloxazine hydrochloride
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00956 Viloxazine
D02572 Viloxazine hydrochloride
DG02924 UGT substrate
DG03188 UGT1A9 substrate
DG00956 Viloxazine
D02572 Viloxazine hydrochloride
DG03187 UGT2B15 substrate
DG00956 Viloxazine
D02572 Viloxazine hydrochloride
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D02572 Viloxazine hydrochloride (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02572
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02572
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02572
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
DG00956 Viloxazine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00956 Viloxazine
DG02924 UGT substrate
DG03188 UGT1A9 substrate
DG00956 Viloxazine
DG03187 UGT2B15 substrate
DG00956 Viloxazine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 18
1 X Cl 17.1500 -18.2000
2 O2a O 9.1982 -19.5713
3 C1b C 7.9455 -20.2672
4 C1y C 6.7625 -19.5713
5 O2x O 5.5795 -20.2672
6 C1x C 4.3269 -19.5713
7 C1x C 4.3269 -18.1795
8 N1x N 5.5795 -17.4836
9 C1x C 6.7625 -18.1795
10 C8y C 9.1982 -18.1713
11 C8y C 10.3772 -17.4909
12 C8x C 10.3775 -16.0909
13 C8x C 9.1652 -15.3907
14 C8x C 7.9862 -16.0710
15 C8x C 7.9859 -17.4710
16 O2a O 11.5804 -18.1861
17 C1b C 12.7642 -17.5030
18 C1a C 13.9569 -18.1922
BOND 18
1 2 3 1
2 3 4 1
3 4 5 1
4 5 6 1
5 6 7 1
6 7 8 1
7 8 9 1
8 4 9 1
9 2 10 1
10 10 11 2
11 11 12 1
12 12 13 2
13 13 14 1
14 14 15 2
15 10 15 1
16 11 16 1
17 16 17 1
18 17 18 1
|
|---|